These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28855436)

  • 1. Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
    Sawa A; Chiba T; Ishii J; Yamamoto H; Hara H; Kamma H
    Endocr J; 2017 Nov; 64(11):1115-1123. PubMed ID: 28855436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth suppression of thyroid cancer cells by adenylcyclase activator.
    Yano Y; Kamma H; Matsumoto H; Fujiwara M; Bando H; Hara H; Yashiro T; Ueno E; Ito K; Uchida K
    Oncol Rep; 2007 Aug; 18(2):441-5. PubMed ID: 17611668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor.
    Ohta K; Pang XP; Berg L; Hershman JM
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2633-8. PubMed ID: 9253346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes.
    Qi XF; Kim DH; Yoon YS; Li JH; Song SB; Jin D; Huang XZ; Teng YC; Lee KJ
    Mol Immunol; 2009 Jun; 46(10):1925-34. PubMed ID: 19371952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual antagonistic interactions between the thyrotropin (adenosine 3',5'-monophosphate) and protein kinase C/epidermal growth factor (tyrosine kinase) pathways in cell proliferation and differentiation of cultured human thyroid follicles.
    Kraiem Z; Sadeh O; Yosef M; Aharon A
    Endocrinology; 1995 Feb; 136(2):585-90. PubMed ID: 7835292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
    Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
    Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
    Yi H; Ye T; Ge M; Yang M; Zhang L; Jin S; Ye X; Long B; Li L
    Oncol Rep; 2018 Feb; 39(2):711-720. PubMed ID: 29207150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
    Datta NS; Chen C; Berry JE; McCauley LK
    J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase.
    Tamir A; Granot Y; Isakov N
    J Immunol; 1996 Aug; 157(4):1514-22. PubMed ID: 8759733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation.
    D'Angelo G; Lee H; Weiner RI
    J Cell Biochem; 1997 Dec; 67(3):353-66. PubMed ID: 9361190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation.
    Chin EC; Abayasekara DR
    J Endocrinol; 2004 Oct; 183(1):51-60. PubMed ID: 15525573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts.
    Kanno Y; Ishisaki A; Yoshida M; Nakajima K; Tokuda H; Numata O; Kozawa O
    Mol Cell Endocrinol; 2005 Jan; 229(1-2):75-82. PubMed ID: 15607531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenylyl cyclase 3/adenylyl cyclase-associated protein 1 (CAP1) complex mediates the anti-migratory effect of forskolin in pancreatic cancer cells.
    Quinn SN; Graves SH; Dains-McGahee C; Friedman EM; Hassan H; Witkowski P; Sabbatini ME
    Mol Carcinog; 2017 Apr; 56(4):1344-1360. PubMed ID: 27891679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3',5'-monophosphate in MCF-7 breast cancer cells.
    Lowe WL; Fu R; Banko M
    Endocrinology; 1997 Jun; 138(6):2219-26. PubMed ID: 9165004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro.
    Schmidt CM; McKillop IH; Cahill PA; Sitzmann JV
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1393-9. PubMed ID: 10654800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
    Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
    Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.